Non-Current Assets

Equity Securities (FV-NI and No Readily Determinable FV)

Gilead Sciences Equity Securities (FV-NI and No Readily Determinable FV) increased by 49.9% to $8.34B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 41.6%, from $5.89B to $8.34B.

Analysis

StatementBalance Sheet Statement
SectionNon-Current Assets
First reportedQ4 2023
Last reportedQ3 2025
Metric ID: equity_securities_fvni_no_fv

Historical Data

8 periods
 Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25
Value$6.55B$4.04B$3.66B$5.89B$10.79B$8.14B$5.57B$8.34B
QoQ Change—-38.4%-9.4%+61.1%+83.1%-24.5%-31.7%+49.9%
YoY Change————+64.8%+101.8%+52.2%+41.6%
Range$3.66B – $10.79B
CAGR+14.9%
Avg YoY Growth+65.1%
Median YoY Growth+58.5%

Frequently Asked Questions

What is Gilead Sciences's equity securities (fv-ni and no readily determinable fv)?
Gilead Sciences (GILD) reported equity securities (fv-ni and no readily determinable fv) of $8.34B in Q3 2025.
How has Gilead Sciences's equity securities (fv-ni and no readily determinable fv) changed year-over-year?
Gilead Sciences's equity securities (fv-ni and no readily determinable fv) increased by 41.6% year-over-year, from $5.89B to $8.34B.

Cookie Preferences

We use cookies for analytics. See our Privacy and Cookie Policy.